With a market capitalization (market cap) of $8.33B — a measure of how much the company is worth — Apogee Therapeutics, Inc. is the 1069th most valuable company in Healthcare as of August 19, 2026. Shares trade at $134.57, down +0.01% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Visit websiteAs of August 19, 2026, Apogee Therapeutics, Inc. (APGE) is worth $8.33B — this is its market capitalization, the total value of all its outstanding shares.
Apogee Therapeutics, Inc.’s market cap is $8.33B, which ranks it #1069 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Apogee Therapeutics, Inc. (APGE) shares trade at $134.57, down 0.01% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025